Estimates Revisions Ocugen, Inc. Börse Stuttgart

Stocks

Market Closed - Börse Stuttgart 23:46:18 18/09/2026 +04			5-day change	1st Jan Change
0.9110 ^EUR	+2.82%		+0.57%	-30.51%

09-01	Ocugen Doses First Patient in Trial of Potential Eye Disease Drug	MT
09-01	Ocugen Doses First Patient in Phase 3 Registrational Trial of Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	LONZA GROUP AG
	IQVIA HOLDINGS INC.
	REVOLUTION MEDICINES, INC.
	BEONE MEDICINES AG
	CELLTRION, INC.
	MEDPACE HOLDINGS, INC.
	ASCENDIS PHARMA A/S			-
	EUROFINS SCIENTIFIC SE
	ICON PUBLIC LIMITED COMPANY
	Average
	Weighted average by Cap.